Answers are grounded in this paper and cite their sources.
Cathepsin S (CatS) is a protease that, unlike most human cysteine cathepsins, remains active at neutral pH, enabling functions in both the endolysosomal compartment and the extracellular space. It primes antigen presentation, remodels the extracellular matrix, and cleaves cytokines and receptors, placing it at the heart of inflammation, autoimmunity, pain, and cancer when its expression or activity is dysregulated. Despite the setbacks of CatK inhibitors, which warn against complete protease shutdown, the approval of brensocatib (a CatC/DPP1 inhibitor) for bronchiectasis supports the feasibility of therapeutic targeting of CatS. This review dissects how CatS is regulated, maps its substrates and roles in disease, and updates the landscape of natural and synthetic inhibitors that bind inside or outside the active site of the enzyme. Finally, it discusses emerging strategies for selective modulation of CatS activity.
No takes yet. Share an insight, caveat, or question.
David et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: